Healthcare
Talphera, Inc.(TLPH)
Live Price
Offline$1.09
+12.37% today
1Y Change
+136.96%
Window
Jun 20, 2025 โ Jun 18, 2026
- Market Cap
- $20.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +32.0%
- Dividend Yield
- 0.0%
Coverage: 250 bars ยท Jun 20, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Talphera, Inc. (TLPH) is a Healthcare stock with a market cap of $20.00M and listed on NASDAQ. The stock last traded around $1.09 and up 137.0% across the available one-year price window (Jun 20, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +32.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +32.0%, free cash flow +10.4% with operating margin -48157.1% and ROIC -52.0%. Valuation already assumes a fairly strong business story at price/sales 673.1. Stock Foundry combines TLPH price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
-48157.1% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report landed above expectations
2026 was reported on May 13, 2026 with an EPS surprise of +42.9%.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +32.0%, while operating margin sits near -48157.1%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 13, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -4.3% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 13, 2026 | +42.9% | +0.0% | -8.9% | -7.8% |
2026 Mar 23, 2026 | +20.0% | -8.7% | -6.3% | -5.0% |
2025 Nov 12, 2025 | -46.7% | -18.6% | +2.3% | -7.8% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TLPH
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
TLPH Max Drawdown
-50.68%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for TLPH and SPY.
Company Overview
Talphera, Inc.
NASDAQ Global Market
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. Talphera, Inc. was incorporated in 2005 and is headquartered in San Mateo, California.
- Leadership
- Vincent J. Angotti
- IPO Date
- Feb 11, 2011
- Employees
- 13
- Street Address
- 1850 Gateway Drive
- Mailing
- San Mateo, CA, 94404
- Region
- San Mateo, CA, US
- Reporting Currency
- USD
- Investor Line
- 650 216 3500
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 673.1
- Price/Book
- 2.3
Growth
- Revenue
- 0.0%
- EPS
- +32.0%
- Free Cash Flow
- +10.4%
Profitability
- Gross Margin
- -4075.0%
- Operating Margin
- -48157.1%
- Net Margin
- -51035.7%
- ROE
- -118.0%
- ROIC
- -52.0%
Balance Sheet
- Debt/Equity
- 0.38
- Current Ratio
- 5.49
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.